Company
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 5 of 16
Avion Pharmaceuticals will also request the FDA consider conditional approval of the drug, whilst the final-stage trial is taking place
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The group said the US Food & Drug Administration has agreed to accept a submission made by Avion Pharmaceuticals supporting a request for a Type-A meeting
We take a closer look at ImmuPharma, the developer of a breakthrough drug for lupus
Looking ahead, the firm said it is awaiting final FDA guidance prior to commencing patient recruitment for a Phase III trial of Lupuzor, its proposed lupus treatment
The group said its licensing partner, Avion has confirmed that as yet it has not received a response from the regulator and as such the file is still in the review queue, due to the current workload at the FDA
Chairman Tim McCarthy said the company was now in an “extremely robust position”
The special assessment protocol is a process that decides on the design and size of the study that will both meet the scientific and regulatory requirements and supports marketing approval for new drugs such as Lupuzor
L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund will receive unsecured convertible securities and associated options
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The drug development firm said the findings of the study suggested that coronavirus patients and lupus sufferers might share similar inflammatory symptoms, underpinned by similar mechanisms
The update was provided alongside full-year 2019 results
The funds have been raised through share subscriptions from chief scientific officer Robert Zimmer as well as significant shareholder Lanstead Capital
Incanthera, which specialises in cancer treatments, is expecting to list on 28 February
The UK company and its American partner concluded their first joint steering committee recently
The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma's shares with European investors, the group said.
The group said the new listing does not affect the trading of its shares on AIM, nor is there any intention for it to raise additional funds from either AIM or Euronext
Investment bank Life Sciences Division upgraded its share price target to 100p from 76p on the back of the recent deal with US speciality drugs group Avion Pharmaceuticals
A look back at some of the more interesting stories from London's junior market this last week
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
